June 20, 2012
Inhibitors Of Shuttle Molecule Show Promise In Acute Leukemia
-An estimated 10,200 Americans will die of acute myeloid leukemia (AML) in 2012, so new ways of treating the disease are needed.
-This study uses a novel class of experimental drugs to halt a process that helps AML cells develop and survive.
-The findings show that the agent is promising and should be considered for clinical trials testing.
A novel family of experimental agents that blocks a molecule from shuttling proteins out of the cell nucleus might offer a new treatment for people with acute leukemia, according to a study by researchers at the Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
In the animal model of AML, KPT-SINEs — described by the researchers as one of the most advanced agents in pre-clinical development — extended survival by 46 percent compared with controls.
KPT-SINEs were particularly effective when the leukemia cells also had mutations in the tumor-suppressor gene NPM1, which are present in about one-third of all adult AML.
The findings were published online in the journal Blood.
“Our study suggests that these agents might be an effective therapy for AML, particularly for patients with NPM1 mutations,” says principal investigator Dr. Ramiro Garzon, assistant professor of medicine and a researcher with the OSUCCC — James Molecular Biology and Cancer Genetics Program.
“We hope to start a phase I trial using one of these agents soon and to pursue further preclinical studies using this drug in combination with other current chemotherapies,” Garzon says.
CRM1 normally transports molecules out of the cell nucleus to the surrounding cytoplasm. In acute leukemia cells, the molecule carries tumor-suppressor, apoptotic and other protective proteins out of the nucleus, thereby contributing to leukemia development.
Karyopharm Therapeutics, Inc., developed KPT-SINEs. This study also showed that these agents:
-Reduce the amount of CRM1 protein in the nucleus and increase the amount of tumor-suppressor protein such as p53 and NPM1 in AML cells.
-Strongly down-regulate FLT3 and KIT, oncogenes that are commonly overexpressed in AML.
-Increase survival in a leukemia animal model, with treated mice living an average of 39 days versus 27 days for untreated animals.
Funding from the NIH/National Cancer Institute (grant CA140158) and a Pelotonia Fellowship award supported this research.
Other researchers involved with this study were Parvathi Ranganathan, Xueyan Yu, Caroline Na, Ramasamy Santhanam, Alison Walker, Rebecca Klisovic, William Blum, Michael Caligiuri, Carlo M. Croce and Guido Marcucci of Ohio State University; and Sharon Shacham and Michael Kauffman of Karyopharm Therapeutics, Inc.
The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only seven centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State´s cancer program as “exceptional,” the highest rating given by NCI survey teams. As the cancer program´s 210-bed adult patient-care component, The James is a “Top Hospital” as named by the Leapfrog Group and one of the top 20 cancer hospitals in the nation as ranked by U.S.News & World Report.
On the Net: